< Back to latest news & events

AGRITECH + IP

Agritech Thymes: A review of protection for gene edited plants

September 2025

As we head into a new season, it’s a good time to revisit the current status of protection for Essentially Derived Varieties (EDVs) and plants derived from New Genomic Techniques (NGTs).

The “Breeders Exemption” allows the development of new varieties from a protected variety without having to wait for the initial PVR to expire. If the new variety falls within the definition of an EDV, as set out below, its owner will need permission from the initial PVR holder in order to commercialise it, so providing some economic recompense to the PVR owner.  If a third party, for example another breeder, wants to use that EDV, they would need permission from both the PVR owner and the new EDV owner. Any new EDV may itself be protected by a PVR, provided it meets the requirements of stability, uniformity and distinctiveness.

As a reminder, an EDV is a plant which is “predominantly derived” from the initial variety – meaning that it has more of the genome of the original variety from which it is derived than would be expected from a normal cross. It must also retain the expression of “essential characteristics” of the initial variety, and be “distinguishable” from the initial variety by one or more characteristics which are capable of a precise description.

Of course, an EDV may be used to generate further EDVs. But when considering protection, it is important to remember that the PVR only extends to the first “generation” of EDVs.  So, if a party is planning to use an EDV generated from an earlier EDV, they would need permission from the initial PVR holder (until the PVR ceases) and from the owner of the last EDV from which it is derived if this is protected by a PVR, but not from the owners of any intermediate EDVs. This becomes interesting when we look at how New Genomic Techniques are being used to generate new plant varieties.

It has been acknowledged by Defra and UPOV that an EDV may be produced from the initial variety by methods including genetic engineering, including precision breeding techniques. However, in 2023 UPOV issued non-binding Explanatory notes which suggested that an EDV does not need to completely share the essential characteristics of the initial variety, as long as the missing essential characteristics are missing as a result of the act of derivation. These Explanatory notes have been interpreted as broadening the definition of an EDV to encompass offspring plants which do not share all essential characteristics with the initial variety. Because the initial PVR provides protection for the first generation EDV but not for intermediate EDVs, if all NGT plants fall within the definition of an EDV then the effective scope of protection of the PBR would be reduced because a greater number of gene edited plants may fall within an intermediate EDV category.

Over a year since the Explanatory Notes have been issued, there remains uncertainty in the field regarding the scope of PBR protection for precision bred EDVs.

In addition, further talks on how to simplify and accelerate the approval process for NGT plants have recently been halted, as the parties have been unable to agree on several issues including labelling of NGT plants. It is hoped that agreement will be reached and the proposed regulation finalised during the Danish presidency in the second half of 2025.

For the time being, HGF’s advice remains to continue with existing patent and PVR filing strategies.


This article was prepared by Partner & Patent Attorney Punita Shah.

Latest updates

A New Era for AI Patents in the UK: Supreme Court Aligns with the EPO

The UK Supreme Court has handed down its long-awaited judgment in Emotional Perception AI Limited (EPAI) vs Comptroller General of Patents, a decision which serves to significantly change the way …

Read article
Event - 23rd - 25th March 2026

HGF are Gold Sponsors of IPBC Europe 2026

HGF are proud sponsors of IPBC Europe 2026, taking place from 23-25 March 2026 at the Pullman Paris Montparnasse. Bringing together patent pioneers, in-house leaders and private practice specialists, IPBC …

Event details
Event - 8th - 11th February 2026

AUTM Meeting 2026

We are attending the AUTM Annual Meeting from 8–11 February, a flagship event bringing together technology transfer professionals from across the globe. AUTM connects innovators, universities, and industry leaders to …

Event details

The Antibody Series #5 | Epitope-defined antibody claims: when “binds to this epitope” becomes a risk of insufficiency

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews decisions made at the EPO; here, they reviewed an appeal in opposition proceedings after the revocation …

Read article

The Deity Shoes case: a question of design activity and the constraints on a designer’s freedom

The footwear brand Deity Shoes sought to enforce their Community Design rights, both registered and unregistered, against Mundorama Confort and Stay Design. However, Mundorama Confort and Stay Design found fault …

Read article

The Antibody Series #4 | pH points in antibody claims: when “same pH ” becomes an addition of matter

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions; in this case, they reviewed a revocation in opposition of a patent relating to …

Read article

The Antibody Series #3 | Antibody code names in claims: why “ACZ885” is not sufficient to define the antibody

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions. In this case, they examined a claim that identified an antibody by an internal …

Read article
Event - 3rd February 2026

HGF Brand & Design Conference 2026

Join us on 3rd February 2026 for HGF’s Brand & Design Conference, the must attend event for in-house legal teams, brand leaders, creatives, and innovators shaping the future of IP. …

Event details